JP2002511886A5 - - Google Patents

Download PDF

Info

Publication number
JP2002511886A5
JP2002511886A5 JP1999512590A JP51259099A JP2002511886A5 JP 2002511886 A5 JP2002511886 A5 JP 2002511886A5 JP 1999512590 A JP1999512590 A JP 1999512590A JP 51259099 A JP51259099 A JP 51259099A JP 2002511886 A5 JP2002511886 A5 JP 2002511886A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1999512590A
Other languages
English (en)
Japanese (ja)
Other versions
JP4291884B2 (ja
JP2002511886A (ja
Filing date
Publication date
Priority claimed from US08/911,383 external-priority patent/US6110461A/en
Application filed filed Critical
Publication of JP2002511886A publication Critical patent/JP2002511886A/ja
Publication of JP2002511886A5 publication Critical patent/JP2002511886A5/ja
Application granted granted Critical
Publication of JP4291884B2 publication Critical patent/JP4291884B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP51259099A 1997-08-13 1998-08-12 新形成の治療用レオウイルス Expired - Lifetime JP4291884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/911,383 US6110461A (en) 1997-08-13 1997-08-13 Reovirus for the treatment of neoplasia
US08/911,383 1997-08-13
PCT/CA1998/000774 WO1999008692A1 (en) 1997-08-13 1998-08-12 Reovirus for the treatment of neoplasia

Publications (3)

Publication Number Publication Date
JP2002511886A JP2002511886A (ja) 2002-04-16
JP2002511886A5 true JP2002511886A5 (https=) 2005-05-12
JP4291884B2 JP4291884B2 (ja) 2009-07-08

Family

ID=25430159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51259099A Expired - Lifetime JP4291884B2 (ja) 1997-08-13 1998-08-12 新形成の治療用レオウイルス

Country Status (14)

Country Link
US (9) US6110461A (https=)
EP (3) EP1003534B1 (https=)
JP (1) JP4291884B2 (https=)
AT (1) ATE213948T1 (https=)
AU (1) AU731810B2 (https=)
CA (1) CA2283280C (https=)
DE (2) DE1003534T1 (https=)
DK (1) DK1003534T3 (https=)
ES (1) ES2157870T3 (https=)
GR (1) GR20010300030T1 (https=)
IL (1) IL131598A (https=)
NZ (1) NZ337493A (https=)
PT (1) PT1003534E (https=)
WO (1) WO1999008692A1 (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
EP1955703A1 (en) 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020156039A1 (en) * 2000-07-07 2002-10-24 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20020147996A1 (en) * 2000-07-07 2002-10-10 Benjamin Thomas L. Diagnosing and treating cancer cells using Sal2
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
BR0115235A (pt) 2000-11-09 2003-10-14 Oncolytics Biotech Inc Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
JP2004513184A (ja) * 2000-11-20 2004-04-30 オンコリティクス　バイオテック，　インコーポレイティッド 固形腫瘍塊への最適なウイルス送達法
WO2002042468A2 (en) 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
JP2004519431A (ja) * 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
DK2253701T3 (da) 2001-03-16 2014-10-20 Oncolytics Biotech Inc Fremgangsmåde til ekstraktion af en virus fra en cellekultur
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
CA2374388C (en) * 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
US7319001B2 (en) 2002-03-09 2008-01-15 Neurogenex Co., Ltd. High throughput system for producing recombinant viruses using site-specific recombination
CA2482512C (en) 2002-04-30 2011-09-20 Oncolytics Biotech Inc. Improved viral purification methods
EP1944035A1 (en) 2002-05-09 2008-07-16 Oncolytics Biotech Inc. Method for reducing pain using oncolytic viruses
DE03722131T1 (de) * 2002-05-09 2005-09-15 Oncolytics Biotech, Inc., Calgary Methode zur schmerzbekämpfung mit onkolytischen viren
US7612039B2 (en) * 2002-06-12 2009-11-03 Temple University - Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060241178A1 (en) * 2002-12-30 2006-10-26 Immuneguard Llc Compositions and methods for treating lung cancer
DE602004018284D1 (de) 2003-03-27 2009-01-22 Ottawa Health Research Inst Mutante vesicular stomatitis viren und deren verwendungen
US7731974B2 (en) * 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
CA2575591A1 (en) * 2003-08-08 2005-02-17 Yuji Shino A pharmaceutical composition for treatment of cancers
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
WO2005030139A2 (en) * 2003-09-26 2005-04-07 Novartis Ag Seneca valley virus based compositions and methods for treating disease
US20050137152A1 (en) * 2003-12-19 2005-06-23 Danny Cheung Reovirus for the prevention of neoplasia
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US20070190032A1 (en) * 2006-02-13 2007-08-16 Oncolytics Biotech Inc. Use of Local Immune Suppression to Enhance Oncolytic Viral Therapy
CA2663034C (en) 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9428736B2 (en) 2010-09-02 2016-08-30 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
WO2014204275A1 (ko) * 2013-06-21 2014-12-24 한국생명공학연구원 리오바이러스를 유효성분으로 함유하는 혈관신생 억제용 조성물
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
WO2021235685A1 (ko) * 2020-05-20 2021-11-25 바이로큐어 주식회사 암 예방 또는 치료용 약학적 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108983A (en) * 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
NL7812359A (nl) * 1978-12-20 1980-06-24 Gist Brocades Nv Vaccins tegen door reo virus veroorzaakte ziektever- schijnselen en werkwijze voor het bereiden van deze vaccins.
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
US4559229A (en) * 1982-07-20 1985-12-17 Research Foundation Avian proventriculitis vaccine
WO1990009441A1 (en) * 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
ATE199568T1 (de) * 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
US5525342A (en) * 1994-05-20 1996-06-11 Akzo Nobel, N.V. Reovirus strain 2177 and vaccine containing same
US5853716A (en) * 1995-07-28 1998-12-29 Yale University Genetically engineered chimeric viruses for the treatment of diseases associated with viral transactivators
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU4352997A (en) 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
AR028039A1 (es) * 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
BR0115235A (pt) * 2000-11-09 2003-10-14 Oncolytics Biotech Inc Métodos de determinar a suscetibilidade de uma célula à infecção por reovìrus, e, uso de uma composição compreendendo um ou mais reovìrus
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2003094939A1 (en) * 2002-05-10 2003-11-20 Oncolytics Biotech Inc. Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2007025365A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
JP5577103B2 (ja) * 2007-03-12 2014-08-20 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス

Similar Documents

Publication Publication Date Title
JP2000509942A5 (https=)
JP2000507042A5 (https=)
JP2000509635A5 (https=)
JP2000509912A5 (https=)
JP2000509637A5 (https=)
JP2000510751A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2000508841A5 (https=)
JP2001522270A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508836A5 (https=)
JP2000508102A5 (https=)
JP2000509818A5 (https=)
JP2000509520A5 (https=)
JP2000507434A5 (https=)